SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

Read more breaking news

 

 

Saltigo says climbing costs drove 1,2,4-triazole and chloroformate price hike

By Gareth Macdonald , 07-Jan-2013
Last updated on 07-Jan-2013 at 13:30 GMT

Saltigo says climbing raw materials, energy and shipping costs prompted it to increase the price of key chemical intermediates, 1,2,4-triazole and chloroformate.

The German firm increased what it charges for the two intermediates – which are used in the production of active pharmaceutical ingredients (API) – by 10 to 20 per cent across the board on January 1.

Saltigo explained that: “The reasons for the measure are increases in raw material, energy and logistic costs,” adding that it reflects the “continued increase in operational costs associated with the safe production.”

The price hike comes just months after Saltigo’s owner –chemicals firm Lanxess AG – reported a 9 per cent increase in revenue generated by its advanced intermediates business for fiscal 2012, citing “higher selling prices, positive volumes and currency effects” as key drivers.

Earnings generated by the intermediates unit – which comprises Saltigo and Lanxess’ Industrial intermediates division - also increased 10 per cent to €70m driven mainly due to higher demand from the agrochemicals sector.

Chloroformate investment

Despite the increase in raw materials costs, Saltigo clearly thinks there is potential for growth in the chloroformate market.

Spokesman Tony Jones said: “Saltigo intends to further develop and strengthen its presence in the important chloroformate market employing its expertise and knowledge of this demanding and challenging chemistry. 

The comments echo those of owner Lanxess earlier this week when said a newly secured, long-term €1.25bn credit facility will be used as a financial back up for its growth strategy.

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions